Are you Dr. Schranz?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 9 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
51 Goldfinch Cir
Phoenixville, PA 19460Phone+1 610-585-6294
Summary
- Dr. Jennifer Schranz, MD is an infectious disease specialist in Phoenixville, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania.
Education & Training
Stony Brook Medicine/University HospitalFellowship, Infectious Disease, 1993 - 1995
University of Toronto Faculty of MedicineClass of 1989
Certifications & Licensure
PA State Medical License 1998 - 2024
Publications & Presentations
PubMed
- 45 citationsPharmacokinetics of Solithromycin (CEM-101) after Single or Multiple Oral Doses and Effects of Food on Single-Dose Bioavailability in Healthy Adult SubjectsJ. Gordon Still, Jennifer Schranz, Thorsten P. Degenhardt, Drusilla Scott, Prabhavathi Fernandes
Antimicrobial Agents and Chemotherapy. 2011-05-01 - 28 citationsA phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis.Jose A. Vazquez, Jennifer Schranz, Kay Clark, Beth P. Goldstein, Annette C. Reboli
Journal of Acquired Immune Deficiency Syndromes. 2008-07-01 - 592 citationsAnidulafungin versus Fluconazole for Invasive CandidiasisAnnette C. Reboli, Coleman Rotstein, Peter G. Pappas, Stanley W. Chapman, Daniel H. Kett
The New England Journal of Medicine. 2007-06-14
Press Mentions
Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (Lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)October 15th, 2019
Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical AssociationSeptember 27th, 2019- Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults with Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical TrialSeptember 27th, 2019
- Join now to see all
